Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.45 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2823619 | 0.86 | ANPEP (0.48) | ANPEPPTGDR2 | |
| SCHEMBL2825476 | 0.84 | TP53 (0.41) | PTGDR2HDAC1HDAC2ALDH1A1TP53 | |
| SCHEMBL2825967 | 0.84 | ANPEP (0.48) | ANPEPHDAC1HDAC2ALDH1A1TP53 | |
| SCHEMBL2825413 | 0.81 | ALDH1A1 (0.54) | HDAC1HDAC2ALDH1A1TP53LMNA | |
| SCHEMBL29456287 | 0.81 | ALDH1A1 (0.54) | HDAC1HDAC2ALDH1A1TP53LMNA | |
| SCHEMBL2006506 | 0.80 | ANPEP (0.49) | ANPEPPTGDR2PARK7HDAC1HDAC2 | |
| SCHEMBL8708926 | 0.71 | PARK7 (0.63) | PARK7ALDH1A1 | |
| SCHEMBL661264 | 0.70 | PER2 (0.42) | ANPEPPTGDR2ALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL7842132 | 0.68 | MEN1 (0.68) | LMNA | |
| SCHEMBL3711385 | 0.67 | ALDH1A1 (0.47) | PTGDR2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799643-B1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | claimed |
| US-7632856-B2 | Indolone derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2009-12-15 | — | — | US | claimed |
| US-20090012147-A1 | Indolone Derivatives, Processes For Preparing Them And Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | claimed |
| EP-1799643-A1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006008067-A1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-01-26 | — | — | WO | claimed |
| EP-1799643-B1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | disclosed |
| US-7632856-B2 | Indolone derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2009-12-15 | — | — | US | disclosed |
| US-20090012147-A1 | Indolone Derivatives, Processes For Preparing Them And Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| EP-1799643-A1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006008067-A1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012147-A1 | Indolone Derivatives, Processes For Preparing Them And Their Uses | IDO1, IDO2, HTR3C | ANPEP 2230/4885PTGDR2 716/4885PARK7 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.